Process Analytical Technology and Process Control in Solid-Dosage Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Process Analytical Technology and Process Control in Solid-Dosage Manufacturing
Industry is moving toward closed-loop control of continuous processing.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 56-61


Fotosearch/Eriko Koga/Comstock/Getty Images; Dan Ward
Since FDA issued its report, Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century—A Risk-Based Approach (1), and its guidance on process analytical technology (PAT) (2) in 2004, academia and industry have been making strides in integrating quality-by-design (QbD) principles and PAT into solid-dosage manufacturing processes.

PAT and QbD principles both emphasize the need for process and material understanding as a basis for effective control of the process. “This emphasis has stimulated the industry to focus on how to get the information it really needs, which is leading to a productive re-examination of the existing analytical toolkit and an embracing of newer technologies that deliver the goods,” says Tim Freeman, managing director for Freeman Technology. Progress has also been made in integrating PAT into continuous manufacturing of finished-drug products, with the eventual goals of closed-loop control and real-time product release.

PAT

Online PAT is successfully being used to optimize individual unit operations in solid-dosage manufacturing by monitoring on-line critical quality attributes (CQAs). Data from PAT give manufacturers better understanding and can be used to control the unit operation. Moisture content, for example, is used to determine the endpoint of a drying cycle. In tableting, the most common online measurements are near infrared (NIR) spectroscopy, which measures moisture content and blend uniformity, and laser-diffraction particle sizing.

Bulk-powder characterization techniques, which are performed at-line or in the laboratory, also fulfill the purpose of PAT by providing crucial information in a timely manner. “Precisely quantifying the flow behavior of powders, either as raw materials or as a blend, and other characteristics such as the ease with which a powder entrains and releases air, supports the development of more efficient processes,” explains Freeman. Flow-property measurements are increasingly being recognized as a desirable online measurement, but this technology is not yet available.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here